# A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

> **NCT06132945** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma
- Brain Metastases

## Interventions

- **DRUG:** Cabozantinib
- **DEVICE:** Nivolumab
- **RADIATION:** Stereotactic Radiosurgery (SRS)

## Key facts

- **NCT ID:** NCT06132945
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-10
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2025-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06132945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06132945, "A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06132945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*